RNA

RNA is currently trading in a 'Special Situation' regime following the announcement of a definitive agreement to be acquired by Novartis for ~$72.00 per share in cash, plus the distribution of a cardiology-focused 'SpinCo' to shareholders. The 'Quiet Storm' signal (low volatility) and 'Realized Volatility' of 2.2% are artifacts of this merger arbitrage dynamic, where the price is effectively pinned to the deal terms. The stock trading at $72.74 (a premium to the $72 cash offer) confirms that the market is assigning approximately $0.74/share of implied value to the upcoming SpinCo stub, rather than anticipating a higher cash bid.